You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Guard Therapeutics presents top-line results of Phase 2 (AKITA) study, 2023
By Inderes
Speaker: Tobias Agervald, CEO and Michael Reusch, CMO
Sector: Health care - Pharmaceuticals & Biotechnology
Activity: Audiocast with teleconference
Language: English
Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data
Introduction to the Helsinki Stock Exchange | Company Night Dec. 16, 2024
Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
GomSpace – Management Q&A
ExpreS2ion Biotech – A look back at 2024 with CEO
View all videos